Invention Grant
- Patent Title: Discovery of FDA-approved drugs as inhibitors of fatty acid binding protein 4 using molecular docking screening
-
Application No.: US14920892Application Date: 2015-10-23
-
Publication No.: US09968616B2Publication Date: 2018-05-15
- Inventor: David Chi Cheong Wan , Yan Wang , Wai Kit Law , Jian Shu Hu , Tsz Ming Ip
- Applicant: The Chinese University of Hong Kong
- Applicant Address: CN Hong Kong
- Assignee: THE CHINESE UNIVERSITY OF HONG KONG
- Current Assignee: THE CHINESE UNIVERSITY OF HONG KONG
- Current Assignee Address: CN Hong Kong
- Agency: Law Offices of Albert Wai-Kit Chan, PLLC
- Main IPC: A61K31/5383
- IPC: A61K31/5383 ; A61K31/00
Abstract:
Using molecular docking screening, a few therapeutical compounds including trovafloxacin and levofloxacin have been first identified as potential inhibitors of fatty acid binding protein 4 (FABP4). The present invention provides a novel use of levofloxacin as an inhibitor of FABP4 and a drug for the treatment of metabolic diseases or a cardiovascular diseases. The present invention further provides a method of using levofloxacin to inhibit FABP4, or to inhibit adipolysis in adipocytes.
Public/Granted literature
Information query
IPC分类:
